Copy of rx capabilities
description
Transcript of Copy of rx capabilities
Overview of Investor Relations Capabilities
ABOUT Rx COMMUNICATIONS
Specialists in the life science and healthcare industries
Partner-driven -- Senior level counsel on EVERY account
Partners have been through up and down market cycles, various political healthcare agendas and technology trends
ABOUT Rx COMMUNICATIONS
Experience with private and public companies – domestic and international
Focused on what we do best: Investor Relations and Financial Media Relations
Strong Wall Street and media contacts
Headquartered in New York City
PRIVATE COMPANIES
Services for Private Companies
WHY EMBARK ON AN IR/PR PROGRAM AS A PRIVATE COMPANY? Lay the groundwork for future
financings and eventual IPO
Assist with partnering activities by building corporate awareness
Build awareness of disease indications to generate product interest
Align company with reputable bankers
Become accustomed to working within disclosure rules i.e.; Reg FD
PROVIDING VALUE TO PRIVATE COMPANIES
Develop key messages positioned for analysts and investors
Develop collateral materials to tell story integrating key messages
Target and facilitate introductions to venture capitalists and institutional investors
Target and advise on corporate finance team
Target and facilitate introductions to sell-side analysts
PROVIDING VALUE TO PRIVATE COMPANIES
Build presence on the web
Develop story ideas for the media
Cultivate reporter interest
Introduce to conference circuit
Properly position company news
Develop company disclosure policy
ACTIVITIES SUROUNDING IPO
Assist in the selection of banking team – beginning of quiet period
Press release announcing registration for offering
Develop roadshow presentation Supplement banker’s list of target
institutions Presentation training
ACTIVITIES SURROUNDING IPO
“Teach-ins” at banks Roadshow Press release announcing completion
of IPO “Welcome letter” to new shareholders Create disclosure policy Quiet period lasts for 25 days
following the close of IPO
PUBLIC COMPANIES
Services for Public Companies
AFTER-MARKET SUPPORT
Need for continual dialogue with shareholders
On-going targeting of investors for future financings
Increase analyst coverage beyond banking support
Fulfill disclosure requirements Crisis communications Strategic media out-reach
GETTING STARTED: FIRST STEPS
Strategy session in order to immerse ourselves in corporate story
Define key message points Understand perceptions existent in
the marketplace Create targeted list of sell-side
analysts, venture capitalists and fund managers
GETTING STARTED: FIRST STEPS
Review collateral materials Create VIP blast e-mail/fax lists Develop media lists Design action plan
Rx COMMUNICATIONS CAPABILITIES
Strategic Counsel Roadshows Analyst Contact Investor Targeting Investment and Industry Conferences Follow-up and Analysis to Key Events Press Release Writing News Conferences/Press Briefings Video/Radio News Releases Fact Sheets Annual Reports
Rx COMMUNICATIONS CAPABILITIES
Crisis Communications Mergers and Acquisitions Positioning Strategy Perception Audits Conference Calls Presentation Training Placement Strategy Financial, Trade and Local Media
Contacts Slide Presentations Web Site Development
THE Rx TEAM
Melody A. Carey, Co-President
Founded Rx in 2000
Head of Corporate Communications and Spokesperson, Schein Pharmaceutical, Inc.
Director of Investor Relations, The Multicare Companies, Inc.
Executive, Noonan/Russo Communications
Former healthcare/life sciences investment banker, Kidder, Peabody & Co.
THE Rx TEAM
Rhonda Chiger, Co-President
Founded Rx in 2000
Senior Managing Director, Global Consulting Practice, Thomson Financial
Managed Life Sciences departments for Noonan/Russo and Dewe Rogerson
Established London office for healthcare investor relations firm
Former Manager, Investor Relations, American Stock Exchange
The Rx Team
Eric Goldman, Vice President
25 years experience in public relations and as a media relations strategist specializing in biotechnology, healthcare, technology and consumer products
Senior Director and Vice President at GlobalFluency
Handled media relations at Spector & Associates and Brouillard Communications, a division of J. Walter Thompson
Earned 2 Silver Anvil awards for public relations excellence
THE Rx TEAM
Tina Posterli, Senior Media Director
More than 14 years experience in public relations and marketing communications
Handled public relations for the Tourette Syndrome Association
Worked in radio, held senior positions at Ruder Finn Public Relations, Noonan/Russo Communications, March of Dimes and the United Way
THE Rx TEAM
Paula B. Schwartz, Senior Vice President
Former Partner, FRB/Weber Shandwick, oldest and largest Investor Relations firm in the U.S.
Former Vice President, ECOM Consultants, Inc., an investor relations firm
Former Vice President/Director of Investor Relations Programs, KCS&A Public Relations, a public relations and investor relations consultancy
THE Rx TEAM
Judith Sylk-Siegel, Senior Media Director
Former Vice President of Media Relations at FRB/Weber Shandwick
Vice President of Investor/Public Relations at Porter, Levay & Rose
Provided national public relations services to the Fox Chase Cancer Center
Rx COMMUNICATIONS CURRENT CLIENT LIST
Advanced BioHealing, Inc. (Private)
Alexandria Real Estate Equities, Inc. (NYSE: ARE)
Alexion Pharmaceuticals Inc. (Nasdaq: ALXN)
American CareSource Holdings, Inc. (Nasdaq: ANCI)
Cataylst Pharmaceutical Partners, Inc. (Nasdaq: CPRX)
Columbia Laboratories, Inc. (Nasdaq: CBRX)
Continucare Corporation (AMEX: CNU)
Glycotex, Inc. (Private)
The Immune Tolerance Institute, Inc. (Non-Profit
Organization)
Intact Medical Corporation (Private)
MediciNova, Inc. (Nasdaq: MNOV)
Rx COMMUNICATIONS CURRENT CLIENT LIST (cont.)
MethylGene, Inc. (TSX: MYG)
Micromet (Nasdaq: MITI)
Nektar Therapeutics (Nasdaq: NKTR)
NexMed, Inc. (Nasdaq: NEXM)
OptMed, Inc. (Private)
PharmAthene, Inc. (AMEX: PIP)
RHEI Pharmaceuticals (Private)
RXi Pharmaceuticals Corporation (Nasdaq: RXII)
Theratechnologies (TSX: TH)
TorreyPines Therapeutics, Inc. (Nasdaq: TPTX)
Vicus Therapeutics, LLC (Private)
Rx COMMUNICATIONS PROJECT CLIENTS
Alantos AG (Private)
NationsHealth, Inc. (Nasdaq: NHRX)
Marinus Pharmaceiticals, Inc. (Private)
Serono (NYSE: SRA)
TetraLogic Pharmaceuticals (Private)
Investor Relations Consulting Agency to Biotechnology Industry Organization (BIO)
OURx SUCCESSES
Announced alliance between CGI Pharmaceuticals and Serono resulting in broad coverage in the U.S. including BioWorld, BioCentury, VentureWire, New Haven Register and Mass High Tech
An aggressive investor outreach campaign on behalf of Genaissance Pharmaceuticals allowed Genaissance to regain compliance with Nasdaq’s $1 listing rule requirement.
Guided Kos Pharmaceuticals through a failed marketing alliance which caused over two million shares to trade (four times the average daily trading volume) and the stock never dropped below 2%.
OURx SUCCESSES
Helped to grow Alexion Pharmaceuticals’ institutional shareholder base from 30% in 1996 to approximately 85% today.
Initiated on-going relationship between ImpactRx (private company) and The Wall Street Journal resulting in 10 articles citing data and expert commentary from the Company
Announced collaboration between Palatin Technologies and King Pharmaceuticals resulting in broad coverage across broadcast, dailies, trade and on-line media
OURx SUCCESSES
Secured expansive and prominent news coverage of the Series B round of financing raised by privately-held Rib-X Pharmaceuticals. Coverage included Dow Jones/Wall Street Journal on-line, Reuters, the Daily Deal and the front page of BioWorld Today, among other local and trade publications.
Guided ABIOMED on issues management surrounding FDA panel meeting. Put FDA’s request for additional data into perspective with reporters and investors. CNBC interview key part of strategy.
OURx SUCCESSES
Rx Communications Group was honored with the 2008 Stevie Award for Best Investor Relations
Program for work on behalf of specialty
pharmaceutical company, NexMed, Inc.
We are pleased to announce that RxCommunications has been selected by PR Week
as a finalist forBoutique PR Agency of the Year
Rx Communications received an honorable MentionAward from PR News, as part of the PR News Platinum PR
Awards 2003. The award was issued in theFinancial/Investor Relations category, for the company's
work on behalf of Genaissance Pharmaceuticals, Inc.
OURx SUCCESSES
Rx Communications was honored with the 2002 SABREAwards Certificate of Excellence for Building a North
American Investor Base for client Syngenta AG.
We are also pleased to share that our work for ImpactRx has won an Honorable Mention
Award in LACP’s (League of AmericanCommunications Professionals) 2002 Publicity
Campaign Competition.
WHY Rx COMMUNICATIONS?
Specialist industry knowledge and expertise
Personal attention from Rx partners
Decades of experience in strategic counsel and implementation of financial public relations programs
Unique niche in working with private companies
Well versed in IPOs, secondary offerings, PIPEs, venture rounds and mergers and acquisitions
“The Street” knows and trusts us
For Additional Information:Rx Communications Group, LLC
445 Park Avenue10th Floor
New York, NY 10022(917) 322-2568www.RxIR.com